Literature DB >> 20564316

Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor.

Dong Lin1, Jane Bayani, Yuwei Wang, Marianne D Sadar, Maisa Yoshimoto, Peter W Gout, Jeremy A Squire, Yuzhuo Wang.   

Abstract

BACKGROUND: Metastasis is the major cause of prostate cancer deaths. Tumor heterogeneity in both primary and metastatic prostate cancers is a major hurdle in elucidating the mechanisms of metastasis in this disease. To circumvent this obstacle and improve our understanding of prostate cancer metastasis, we developed multiple tumor tissue lines from one patient's primary prostate cancer specimen to examine differences in metastatic ability.
METHODS: Pieces of tissue from different foci of a patient's primary prostate tumor were grafted into subrenal capsules of NOD-SCID mice and transplantable tumor sublines were established by serial passage. The metastatic ability of each subline was tested via orthotopic grafting into mice. Chromosomal alterations exclusively presented in a metastatic subline were examined by SKY and investigated for their presence in parental tissues by fluorescence in situ hybridization.
RESULTS: Three transplantable sublines were developed, resembling the primary tumor histologically, exhibiting poor differentiation, and different growth rates. Importantly, the LTL-220N and LTL-221N sublines were non-metastatic, whereas the LTL-220M subline was spontaneously metastatic in vivo. SKY analysis showed limited but unique chromosomal alterations in each subline. Some chromosomal alterations, exclusively present in the metastatic LTL-220M subline, were also observed in a small portion of the parental cancer tissues.
CONCLUSION: The results indicate that in primary prostate tumors metastatic potential can be confined to a minority of cancer cells. Subrenal capsule xenograft methodology can be used to dissect heterogeneous cancer cells in a patient's primary tumor and sublines derived from such cells provide valuable tools for investigating mechanisms underlying prostate cancer metastasis.

Entities:  

Mesh:

Year:  2010        PMID: 20564316     DOI: 10.1002/pros.21199

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

Review 1.  Patient-Derived Prostate Cancer: from Basic Science to the Clinic.

Authors:  Gail P Risbridger; Renea A Taylor
Journal:  Horm Cancer       Date:  2016-05-13       Impact factor: 3.869

Review 2.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Authors:  Changhong Shi; Xue Chen; Dengxu Tan
Journal:  Transl Androl Urol       Date:  2019-10

3.  Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.

Authors:  Hung-Ming Lam; Holly M Nguyen; Eva Corey
Journal:  Methods Mol Biol       Date:  2018

Review 4.  F-box only protein 9 and its role in cancer.

Authors:  Shujaat Hussain; Jianshu Dong; Xinli Ma; Jian Li; Shen Chen; Agboybor Clement; Hongmin Liu
Journal:  Mol Biol Rep       Date:  2022-01-13       Impact factor: 2.316

Review 5.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

Review 6.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

7.  The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.

Authors:  Chen Jing; Jiang Ning; Niu Yuanjie
Journal:  J Cancer Res Clin Oncol       Date:  2012-08-07       Impact factor: 4.553

8.  Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.

Authors:  Francesco Crea; Akira Watahiki; Luca Quagliata; Hui Xue; Larissa Pikor; Abhijit Parolia; Yuwei Wang; Dong Lin; Wan L Lam; William L Farrar; Takao Isogai; Rudolf Morant; Serenella Castori-Eppenberger; Kim N Chi; Yuzhuo Wang; Cheryl D Helgason
Journal:  Oncotarget       Date:  2014-02-15

9.  Next generation patient-derived prostate cancer xenograft models.

Authors:  Dong Lin; Hui Xue; Yuwei Wang; Rebecca Wu; Akira Watahiki; Xin Dong; Hongwei Cheng; Alexander W Wyatt; Colin C Collins; Peter W Gout; Yuzhuo Wang
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

10.  A preclinical xenograft model of prostate cancer using human tumors.

Authors:  Mitchell G Lawrence; Renea A Taylor; Roxanne Toivanen; John Pedersen; Sam Norden; David W Pook; Mark Frydenberg; Melissa M Papargiris; Birunthi Niranjan; Michelle G Richards; Hong Wang; Anne T Collins; Norman J Maitland; Gail P Risbridger
Journal:  Nat Protoc       Date:  2013-04-04       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.